Übersetzung für "Skin atrophy" in Deutsch

Vigilance is required for possible systemic side effects and skin atrophy.

No cases of skin atrophy were reported.

Side effects can be the following: burning, itching, skin atrophy, acne rosacea.

When applying topical immuno-modulators, skin atrophy known from glucocorticoids is omitted.

The healing of the blisters usually occurs without scarring and skin atrophy.

Healing usually occurs without scarring or skin atrophy.

It follows from this that the prevention of skin atrophy was inseparably tied to the use of the known pharmaceuticals.

Muscle and skin begin to atrophy faster, resulting in bone thinning.

Unlike corticosteroids, pimecrolimus does not cause skin atrophy in pigs and does not affect Langerhans´cells in murine skin.

In prolonged use (beyond 4 weeks), you should look out for possible systemic side effects (e.g. chest pain) and skin atrophy.

In addition, due to the content of the corticosteroid prednisolone in [invented name] , skin atrophy might occur with prolonged use, further increasing systemic exposure to oestradiol.

Adverse events of concern possibly related to long-term corticosteroid use (e.g. skin atrophy, folliculitis, depigmentation, furuncle and purpura) were reported by 4.8 % of the patients in the Daivobet ointment group, 2.8 % in the Daivobet ointment /Daivonex alternating group and 2.9 % in the Daivonex group.”

Local reactions can occur after topical use, especially during prolonged application, including skin atrophy, telangiectasia, striae, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation and colloid milia.

Furthermore, in patients treated with topical media containing cortisone, serious side effects have been found, such as incurable aging of the skin (atrophy).

These properties of the 25-carboxylic acid derivatives in the vitamin D series according to the invention make them appear suitable for therapeutic use in the case of atrophic skin, as it occurs with natural skin ageing, premature skin ageing because of increased exposure to light or medicinally induced skin atrophy by treatment with glucocorticoids.

Their potential side effects, such as suppression of the brain-pituitary gland-suprarenal axis, their catabolic action, their influence on salt and water balance, osteoporosis, their influence on the blood-sugar level in the case of diabetics or the induction of skin atrophy in the case of topical application keep this class of substances from being put to an even broader range of therapeutic uses.

These properties of the vitamin D compounds according to the invention can appear suitable for therapeutic use in atrophic skin, as it occurs in the natural aging of the skin, premature aging of the skin because of increased exposure to light or medicinally-induced skin atrophy by treatment with glucocorticoids.

These properties of the compounds according to the invention make them appear suitable for therapeutic use in the case of atrophic skin, as it occurs with natural skin aging, premature skin ageing because of increased exposure to light or medicinally induced skin atrophy by treatment with glucocorticoids.

Therefore, it is and must always have been an essential aspect in the application of glucocorticosteroids in the treatment of dermatoses to avoid skin atrophy in order not to make the main effect of the glucocorticosteroid meaningless for the patient.

In some circumstances, additional factors join up and further boost the sensitivity of the skin, as for instance the disposition to atopic skin or also atrophy due to adverse effects of pharmaceutical drugs.

Creams containing cortisone show disadvantages after a long-term treatment like skin atrophy which means an increased sensibility towards substances with allergenic potential.

The Appellant himself has additionally referred to document (8) and admitted that skin atrophy is a well-recognised and fully-documented clinical condition occurring after prolonged use of corticosteroids.